Fluidigm (NASDAQ:FLDM) develops, manufactures, and markets microfluidic systems to leading academic institutions, clinical laboratories, and pharmaceutical, biotechnology, and agricultural biotechnology companies in growth markets, such as single-cell genomics, applied genotyping, and sample preparation for targeted resequencing. Fluidigm's proprietary microfluidic systems consist of instruments and consumables, including 18 different commercial integrated fluidic circuits for nucleic acid analysis, and three families of assay chemistries. These systems are designed to significantly simplify experimental workflow, increase throughput, and reduce costs, while providing the excellent data quality demanded by customers.
Missing: Fluidigm's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Fluidigm's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Fluidigm
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Fluidigm is included in 4 Expert Collections, including Medical Devices.
Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.
Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data
Semiconductors, Chips, and Advanced Electronics
Companies in this collection develop everything from microprocessors to flash memory, integrated circuits specifically for quantum computing and artificial intelligence to OLED for displays, massive production fabs to circuit design firms, and everything in between.
Fluidigm has filed 234 patents.
Fluid dynamics, Analytical chemistry, Integrated circuits, Gate arrays, Microfluidics
Fluid dynamics, Analytical chemistry, Integrated circuits, Gate arrays, Microfluidics
Latest Fluidigm News
Jan 17, 2023
| insightSLICE According to estimates, the global market for Polymerase Chain Reaction (PCR) was worth $22.7 billion in 2021 and will expand at a CAGR of 1.1% through 2032. Access the sample report: https://www.insightslice.com/request-sample/1114 Uses of PCR equipment: The polymerase chain reaction is among the most significant, potent, and frequently employed methods in contemporary biology. It is a molecular method for creating millions of clones of a particular section of a DNA strand in vitro. The main reason driving the polymerase chain reaction market growth during the projection timeframe is the increase in the incidence of infectious diseases, cancer, and genetic problems as well as the development in the adoption of equipment for the detection of such diseases. Additionally, it is anticipated that the market would rise during the anticipated period due to rising research and development efforts in sophisticated molecular biology, forensics, the need for customized medications, and genetic engineering. The key players of the Global Polymerase Chain Reaction Market are: The profiles of the top businesses worldwide are provided; the market competition and the market share percentages owned by well-known businesses have been carefully examined and calculated. The report includes company profiles, which include an overview, a list of services offered, operating income, a strategy pursued, and important recent partnerships. In the end, this report will equip the user to make important business decisions. Fluidigm Corporation, Abbott, Thermo Fisher Scientific Inc., Qiagen, Agilent Technologies Inc., Stilla Technologies, F. Hoffmann-La Roche Ltd., Microsynth AG, Bio-Rad Laboratories Inc., JN Medsys, bioMérieux SA, Cytiva, Danaher Corporation, and others are significant market participants in the global Polymerase Chain Reaction market. Read more about the report inclusions: https://www.insightslice.com/polymerase-chain-reaction-market Driving factors for the growth of Global Polymerase Chain Reaction Market Even during the forecast period, the incidence of chronic and infectious conditions as well as genetic problems are anticipated to rise. The CDC estimates that 7 in 10 deaths in the United States occur as a result of chronic conditions such as cancer, hypertension, chronic renal, and respiratory illnesses like asthma. In addition, the prevalence of congenital cardiovascular problems is rising, necessitating the search for genetic diagnostic equipment by medical practitioners to make reliable diagnoses. Congenital heart problems, which afflict around 1% of newborns annually, are the most prevalent deformities in the U.S., based on the CDC data. As a result, during the projection period, there will be greater demand for new molecular diagnostic tests due to the rising prevalence of diseases. The market for polymerase chain reaction testing is also anticipated to rise throughout the projected period due to rising demand for point-of-care and self-testing. Additionally, major industry participants are creating portable, quick, and simple-to-use equipment for use in point-of-care venues. For example, QuantuMDx announced the introduction of the Q-POC technology in July 2021. This system enables quick POC diagnostic kits that are useful for environments like ICUs, hospitals, and maternity facilities. In addition, many POC polymerase chain reaction diagnostics for the diagnosis of COVID-19 disease have been approved in the previous two years. Factors affecting the growth: The need for prenatal genetic testing techniques is predicted to increase as people become more aware of hereditary diseases such as cystic fibrosis, hemophilia, and thalassemia. Employing qPCR and dPCR methods, embryonic DNA that is present in the mother’s blood or the amniotic fluid during the initial stages of pregnancy can be examined to find genetic problems before delivery. Therefore, during the early stages of pregnancy, potential genetic abnormalities and fetuses with genetic defects can be addressed. The utilization of PCR assays in clinical diagnostics is anticipated to rise as technology improves their sensitivity, accuracy, efficiency, and cost-effectiveness. One of the main variables anticipated to propel the market is the growing number of automated instruments as well as associated widespread availability. Additionally, the market is anticipated to be driven by technological advancements and the ensuing emergence of low-cost, highly effective goods. Global Polymerase Chain Reaction Market Key Segments: By End Use The leading market segments of Global Polymerase Chain Reaction Market During the projection period, it is anticipated that the conventional PCR segment would have significant expansion. Traditional PCR is expanding as a result of increased product announcements, increased use of conventional PCR for food safety testing, and other factors. Over 95.0% of the market’s revenue was owned by the dPCR, qPCR, as well as other innovative techniques categories in 2021, and it is projected that they will continue to dominate the market during the forecast period. Over the projection period, the segment is anticipated to be driven by the development of technologically enhanced PCR tests, the rising prevalence of targeted diseases, and the increased application of current technology. The measurement of cell proliferation, disease detection, copy number variability, database verification, viral characterization, SNP sequencing, and microRNA research are just a few of the many uses for new PCR. Regional performance of Polymerase Chain Reaction Market With a market share of over 40% in 2021, North America is expected to keep its lead throughout the projected period. The high incidence of diseases, the existence of important companies in the region, the existence of favorable regulations, and numerous initiatives regarding improvements in healthcare infrastructure initiated by the government, as well as these factors all contribute to the growth of the regional market. An additional aspect influencing the rise is the increasing patient knowledge of the accessibility of contemporary products for successful diagnosis. One of the most lucrative markets in the Asia Pacific, which is giving leaders around the world new possibilities. Global companies are being urged to invest in the Asia Pacific region of the untapped talent, significant unmet medical requirements, and rising healthcare expenditures in the region’s member states. Additionally, during the projection period, PCR consumption is likely to increase due to technological developments and the increased prevalence of several target diseases. In addition, the local businesses’ product releases in new areas to increase their presence are anticipated to support industry growth. Related reports: Global Pharmaceutical Vials Market: https://www.insightslice.com/pharmaceutical-vials-market insightSLICE is a market intelligence and strategy consulting company. The company provides tailor-made and off the shelf market research studies. The prime focus of the company is on strategy consulting to provide end-to-end solutions. For more details, please contact our research and consulting team at firstname.lastname@example.org . Contact us:
Fluidigm Frequently Asked Questions (FAQ)
When was Fluidigm founded?
Fluidigm was founded in 1999.
Where is Fluidigm's headquarters?
Fluidigm's headquarters is located at 2 Tower Place, South San Francisco.
What is Fluidigm's latest funding round?
Fluidigm's latest funding round is PIPE.
How much did Fluidigm raise?
Fluidigm raised a total of $142.7M.
Who are the investors of Fluidigm?
Investors of Fluidigm include Viking Global Investors, Casdin Capital, Alloy Ventures, Versant Ventures, EuclidSR Partners and 16 more.
Who are Fluidigm's competitors?
Competitors of Fluidigm include Lunaphore Technologies.
Compare Fluidigm to Competitors
RareCyte is a life science research and diagnostic development company focused on characterizing and isolating rare cells in the blood. RareCyte is dedicated to bringing its technology to Life Sciences research, drug development, and diagnostic markets providing new tools to answer difficult questions related to cancer and cardiovascular disease.
Lunaphore is a company that develops tissue autostainers for cancer research and tissue diagnostics. It offers solutions such as biomarker discovery, immuno-therapy development, and late-stage translational research across different tissue types and targets to simplify technology adoption for translational research laboratories that develop targeted treatments for cancer and other diseases. It was founded in 2014 and is based in Tolochenaz, Switzerland.
Akoya Biosciences (NASDAQ: AKYA) offers comprehensive, end-to-end solutions for high-parameter tissue analysis from discovery through clinical and translational research, enabling the development of more precise therapies for immuno-oncology and other drug development applications. The company has two platforms that empower investigators and researchers to gain a deeper understanding of complex diseases such as cancer, and other immune system or neurological disorders.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.